Table II.
Association between serum miR-558-3p and miR-885-5p and clinical characteristics of the ccRCC patients.
| miR-508-3p | miR-885-5p | |||||
|---|---|---|---|---|---|---|
| Characteristics | High | Low | P-value | High | Low | P-value |
| Age (years) | ||||||
| ≤60 | 22 | 19 | 19 | 22 | ||
| >60 | 20 | 24 | 0.45 | 23 | 21 | 0.58 |
| Sex | ||||||
| Male | 24 | 21 | 22 | 23 | ||
| Female | 18 | 22 | 0.44 | 20 | 20 | 0.89 |
| T stage | ||||||
| T1+T2 | 37 | 26 | 24 | 39 | ||
| T3+T4 | 5 | 17 | 0.004 | 18 | 4 | <0.001 |
| N stage | ||||||
| N0+NX | 39 | 39 | 37 | 41 | ||
| N1 | 3 | 4 | 0.71 | 5 | 2 | 0.22 |
| M stage | ||||||
| M0+MX | 38 | 29 | 30 | 37 | ||
| M1 | 4 | 14 | 0.009 | 12 | 6 | 0.086 |
| Fuhrman grading | ||||||
| G1+G2 | 31 | 15 | 17 | 29 | ||
| G3+G4 | 11 | 28 | <0.001 | 25 | 14 | 0.013 |
| TNM stage | ||||||
| I+II | 36 | 25 | 27 | 34 | ||
| III+IV | 6 | 18 | 0.005 | 15 | 9 | 0.13 |
ccRCC, clear cell renal cell carcinoma. P-values in bold print indicate statistically significant differences.